Header Logo

Connection

ABBAS RANA to Carcinoma, Hepatocellular

Back to Details
This is a "connection" page, showing publications ABBAS RANA has written about Carcinoma, Hepatocellular.
ABBAS RANA
Connection Strength
1.769
Carcinoma, Hepatocellular
  1. Is Liver Transplant Justified at Any MELD Score? Transplantation. 2023 03 01; 107(3):680-692.
    View in: PubMed
    Score: 0.434
  2. Survival following liver transplantation for hepatocellular carcinoma after implementation of MMaT-3 policy. Liver Transpl. 2023 10 01; 29(10):1138-1142.
    View in: PubMed
    Score: 0.113
  3. Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium. Liver Transpl. 2023 07 01; 29(7):683-697.
    View in: PubMed
    Score: 0.112
  4. Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: results from the US multicenter HCC transplant consortium. Liver Transpl. 2023 01 01; 29(1):34-47.
    View in: PubMed
    Score: 0.110
  5. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era. Clin Gastroenterol Hepatol. 2023 08; 21(9):2288-2297.e4.
    View in: PubMed
    Score: 0.110
  6. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.106
  7. Posttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non-Hepatocellular Carcinoma Factors. Liver Transpl. 2021 05; 27(5):684-698.
    View in: PubMed
    Score: 0.097
  8. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. Hepatology. 2020 12; 72(6):2014-2028.
    View in: PubMed
    Score: 0.095
  9. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Ann Surg. 2020 04; 271(4):616-624.
    View in: PubMed
    Score: 0.091
  10. Impact of the Treating Hospital on Care Outcomes for Hepatocellular Carcinoma. Hepatology. 2018 11; 68(5):1879-1889.
    View in: PubMed
    Score: 0.082
  11. A long-term experience with expansion of Milan criteria for liver transplant recipients. Clin Transplant. 2018 06; 32(6):e13254.
    View in: PubMed
    Score: 0.080
  12. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium. Ann Surg. 2017 09; 266(3):525-535.
    View in: PubMed
    Score: 0.076
  13. Reply: To PMID 24954365. Hepatology. 2015 Oct; 62(4):1328-9.
    View in: PubMed
    Score: 0.065
  14. Reply: To PMID 24954365. Hepatology. 2015 Apr; 61(4):1439.
    View in: PubMed
    Score: 0.064
  15. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology. 2014 Dec; 60(6):1957-62.
    View in: PubMed
    Score: 0.062
  16. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009 Jul; 250(1):141-51.
    View in: PubMed
    Score: 0.043
  17. Cost of Care for Patients With Cirrhosis. Am J Gastroenterol. 2024 03 01; 119(3):497-504.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.